Mesoblast (MESO) Cash from Operations Growth (1y) (2017 - 2023)
Mesoblast (MESO) Cash from Operations Growth (1y) (2017 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Mesoblast | 19.81 Bn | 19.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -17.16% |
| Mar 31, 2023 | -5.04% |
| Dec 31, 2022 | 9.69% |
| Sep 30, 2022 | 21.50% |
| Jun 30, 2022 | 26.56% |
| Mar 31, 2022 | 36.78% |
| Dec 31, 2021 | 40.42% |
| Sep 30, 2021 | 35.39% |
| Jun 30, 2021 | -38.76% |
| Mar 31, 2021 | -23.00% |
| Dec 31, 2020 | -2,199.25% |
| Sep 30, 2020 | -81.05% |
| Jun 30, 2020 | 28.56% |
| Mar 31, 2020 | 6.11% |
| Dec 31, 2019 | -165.55% |
| Sep 30, 2019 | 20.40% |
| Jun 30, 2019 | 5.46% |
| Mar 31, 2019 | -8.09% |
| Dec 31, 2018 | 113.65% |
| Sep 30, 2018 | 3.99% |